View Item 

Show simple item record

The Value of Protocol Biopsies to Identify Patients With De Novo Donorâ Specific Antibody at High Risk for Allograft Loss
dc.contributor.authorSchinstock, C. A.
dc.contributor.authorCosio, F.
dc.contributor.authorCheungpasitporn, W.
dc.contributor.authorDadhania, D. M.
dc.contributor.authorEverly, M. J.
dc.contributor.authorSamaniego‐picota, M. D.
dc.contributor.authorCornell, L.
dc.contributor.authorStegall, M. D.
dc.date.accessioned2017-06-16T20:12:50Z
dc.date.available2018-08-07T15:51:22Zen
dc.date.issued2017-06
dc.identifier.citationSchinstock, C. A.; Cosio, F.; Cheungpasitporn, W.; Dadhania, D. M.; Everly, M. J.; Samaniego‐picota, M. D. ; Cornell, L.; Stegall, M. D. (2017). "The Value of Protocol Biopsies to Identify Patients With De Novo Donorâ Specific Antibody at High Risk for Allograft Loss." American Journal of Transplantation 17(6): 1574-1584.
dc.identifier.issn1600-6135
dc.identifier.issn1600-6143
dc.identifier.urihttps://hdl.handle.net/2027.42/137430
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinduction
dc.subject.otherbiopsy
dc.subject.otherrejection: antibodyâ mediated (ABMR)
dc.subject.otherkidney (allograft) function/dysfunction
dc.subject.otheralloantibody
dc.subject.otherkidney transplantation/nephrology
dc.subject.otherclinical research/practice
dc.subject.otherimmunosuppressive regimens
dc.titleThe Value of Protocol Biopsies to Identify Patients With De Novo Donorâ Specific Antibody at High Risk for Allograft Loss
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137430/1/ajt14161_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137430/2/ajt14161-sup-0001-TableS1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137430/3/ajt14161.pdf
dc.identifier.doi10.1111/ajt.14161
dc.identifier.sourceAmerican Journal of Transplantation
dc.identifier.citedreferenceEverly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donorâ specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410 â 417.
dc.identifier.citedreferenceTerasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2â year prospective trial. Transplantation 2005; 80: 1194 â 1197.
dc.identifier.citedreferenceHourmant M, Cesbronâ Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donorâ specific and nonâ donorâ specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804 â 2812.
dc.identifier.citedreferenceHidalgo LG, Campbell PM, Sis B, et al. De novo donorâ specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532 â 2541.
dc.identifier.citedreferenceWiebe C, Gibson IW, Blydtâ Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donorâ specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157 â 1167.
dc.identifier.citedreferenceClayton PA, Lim WH, Wong G, Chadban SJ. Relationship between eGFR Decline and Hard Outcomes after kidney transplants. J Am Soc Nephrol 2016; 11: 3440 â 3446.
dc.identifier.citedreferenceLevey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64: 821 â 835.
dc.identifier.citedreferenceCoresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of endâ stage renal disease and mortality. JAMA 2014; 311: 2518 â 2531.
dc.identifier.citedreferenceFreitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulinâ G subclasses and C1q in de novo HLAâ DQ donorâ specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113 â 1119.
dc.identifier.citedreferenceGuidicelli G, Guerville F, Lepreux S, et al. Nonâ complementâ binding de novo Donorâ specific antiâ HLA antibodies and kidney allograft survival. J Am Soc Nephrol 2016; 27: 615 â 625.
dc.identifier.citedreferenceWiebe C, Pochinco D, Blydtâ Hansen TD, et al. Class II HLA epitope matchingâ A strategy to minimize de novo donorâ specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114 â 3122.
dc.identifier.citedreferenceHirai T, Furusawa M, Omoto K, Ishida H, Tanabe K. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients. Transplantation 2014; 98: 443 â 450.
dc.identifier.citedreferenceRacusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713 â 723.
dc.identifier.citedreferenceSolez K, Colvin RB, Racusen LC, et al. Banff â 05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (â CANâ ). Am J Transplant 2007; 7: 518 â 526.
dc.identifier.citedreferenceSolez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753 â 760.
dc.identifier.citedreferencede Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donorâ specific antibodies. Am J Transplant 2013; 13: 485 â 492.
dc.identifier.citedreferenceDeVos JM, Patel SJ, Burns KM, et al. De novo donor specific antibodies and patient outcomes in renal transplantation. Clin Transpl 2011; 25: 351 â 358.
dc.identifier.citedreferenceCooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl 2011; 25: 359 â 364.
dc.identifier.citedreferenceWiebe C, Gibson IW, Blydtâ Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donorâ specific antibody. Am J Transplant 2015; 15: 2921 â 2930.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt14161_am.pdf
Size:
452.1KB
Format:
PDF
View/Open
Name:
ajt14161-sup-0001-TableS1.pdf
Size:
46.37KB
Format:
PDF
View/Open
Name:
ajt14161.pdf
Size:
1.441MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.